For a decade, pharma bought the promise that automating patient services would bend the cost curve. For specialty and advanced therapies, that promise has quietly hit a ceiling — and the rework it leaves behind lands on case managers, operating budgets, and the patients who can least afford the delay. Here's how to tell if your brand has reached the automation plateau, and what separates a true patient services partner from a platform.

Jack is 61 and fighting lung cancer, but every treatment cycle stalls behind a prior authorization. The financial model that quietly funded programs like his has collapsed, and most specialty brands haven't changed a thing.

The pitch for electronic benefit verification is compelling and, in isolation, accurate. You submit a handful of data points and receive coverage information in seconds rather than hours or even days. For a system historically dominated by phone trees, fax machines, and hold music, that kind of efficiency sounds like a meaningful leap forward. And for straightforward cases, it is.

The gross-to-net pricing model — long the backbone of pharmaceutical affordability strategy — is under structural pressure. As rebate transparency reforms and direct-to-patient channels reshape how discounts reach patients, pharma's traditional buffer for funding access programs is shrinking. Companies that fail to adapt risk losing both margin and patient trust in an increasingly transparent pricing environment.

A 2025 study found that over 61% felt healthcare chatbots did not fully understand them, while 35% reported they could not fully understand the chatbot (Shah et al., 2025). Those numbers reflect something most people working in patient support already sense: the technology has outpaced the foundation it is supposed to rest on.

COPILOT Provider Services today announced its official rebrand as Elusa Health, marking a significant evolution in the company's identity and its commitment to transforming how patients access therapies in an increasingly complex healthcare system.

When operational breakdowns, compliance lapses, and communication failures begin to directly impact patient care, the need for a true patient services partner becomes undeniable

More than 75% of specialty medications launching today benefit from having FRMs embedded in their field support teams, and for good reason.

When a pharmaceutical partner came to Elusa Health seeking a better way to support patients and providers, what began as a transitional engagement quickly evolved into a story of measurable transformation rooted in reliability, precision, and operational excellence.

Burdened with manual, fax-dependent workflows, low case volumes, poor data quality, and a lack of Field Reimbursement Manager (FRM) support, this manufacturer was struggling to connect patients with the therapies they needed. But after the right transition, they increased case volumes six-fold.

Patient access is the term used to describe the full range of services and processes that help patients obtain the medications they have been prescribed. In specialty and rare disease therapy, this means navigating insurance verification, prior authorization, financial assistance, and ongoing case management so that patients can start and stay on treatment. Patient access exists because the path from a prescription to a dispensed medication is rarely straightforward, and for complex therapies, it almost never is.